NYSE:AGNAllergan Stock Price, Forecast & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Allergan.

Allergan plc (NYSE:AGN) announced its quarterly earnings results on Monday, February, 10th. The company reported $5.22 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $4.57 by $0.65. The business earned $4.35 billion during the quarter, compared to analyst estimates of $4.09 billion. Allergan had a positive return on equity of 8.46% and a negative net margin of 15.44%. The firm's revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the company earned $4.29 EPS.
View Allergan's earnings history.

Allergan announced a quarterly dividend on Wednesday, March 18th. Shareholders of record on Thursday, April 16th will be given a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 annualized dividend and a dividend yield of 1.53%. The ex-dividend date of this dividend is Wednesday, April 15th.
View Allergan's dividend history.

Allergan declared that its Board of Directors has initiated a stock repurchase program on Tuesday, January 29th 2019, which permits the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 4.1% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's board of directors believes its shares are undervalued.

4 equities research analysts have issued twelve-month price targets for Allergan's stock. Their forecasts range from $193.00 to $203.00. On average, they anticipate Allergan's share price to reach $198.00 in the next year. This suggests a possible upside of 2.6% from the stock's current price.
View analysts' price targets for Allergan.

Media headlines about AGN stock have been trending extremely negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allergan earned a news impact score of -4.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.
View the latest news about Allergan.

Allergan saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 15,010,000 shares, an increase of 20.2% from the March 31st total of 12,490,000 shares. Based on an average daily volume of 3,980,000 shares, the short-interest ratio is presently 3.8 days.
View Allergan's Short Interest.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Transocean (RIG) and United Rentals (URI).

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan's stock is owned by a number of retail and institutional investors. Top institutional investors include Ashburton Jersey Ltd (0.06%), Cerebellum GP LLC (0.01%) and Valeo Financial Advisors LLC (0.00%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi and Matthew M Walsh.
View institutional ownership trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Valeo Financial Advisors LLC.
View insider buying and selling activity for Allergan.

AGN stock was purchased by a variety of institutional investors in the last quarter, including Ashburton Jersey Ltd, and Cerebellum GP LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, and Matthew M Walsh.
View insider buying and selling activity for Allergan.

One share of AGN stock can currently be purchased for approximately $193.02.

Allergan has a market capitalization of $63.50 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe.

The official website for Allergan is www.allergan.com.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]